Actively Recruiting
Predictive and Impact of Pain After 6 Months of Radiotherapy, in Head and Neck Cancer
Led by University Hospital, Caen · Updated on 2025-07-25
120
Participants Needed
1
Research Sites
181 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Caen
Lead Sponsor
C
Centre Francois Baclesse
Collaborating Sponsor
AI-Summary
What this Trial Is About
Head and neck cancers are a source of complications and after-effects related to the disease and treatment. These cancers and their treatment alter the quality of life of patients and generate pain with physical and psychological components. Chronic pain affects 36% of patients at 6 months and 30% after this period. These pains are responsible for the consumption of level II and III analgesics in 53% of these patients. At the same time, after the end of treatment, nearly a quarter of patients continued to smoke and half still consumed alcohol at least twice a week. The hypothesis of this research is to investigate the correlation between pain and the continuation of addictions, the occurrence of depressive states, asthenia and the alteration of the patients' global quality of life. The investigators propose a two-center prospective cohort study to evaluate this hypothesis at 6 months after radiotherapy treatment. This study is planned to include 120 patients with a first head and neck cancer whit radiotherapy as part of their treatment sequence. The expected duration of inclusion is 18 months. The identification of factors affecting survival, quality of life and patient compliance is essential to determine appropriate management, particularly by creating appropriate therapeutic education programs.
CONDITIONS
Official Title
Predictive and Impact of Pain After 6 Months of Radiotherapy, in Head and Neck Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with a first Head and neck cancer whose therapeutic sequence involves radiotherapy
- Patient over 18 years of age
- Having given written consent
- Patient not previously treated with radiotherapy
- Life expectancy greater than 3 months
- World Health Organization (WHO) score less than 3
- Histologically proven Head and Neck cancer
- Stable patient, with no signs of recurrence or other progressive neoplasia at the time of the examination
- Patient treated with radiotherapy
- Patient fluent in French
You will not qualify if you...
- Non-consenting patient
- History of malignancy, other than treated and cured basal cell or cervical cancer
- Patient who has had a salvage surgery other than lymph node removal
- Patient with evidence of recurrence or other progressive neoplasia at the time of examination
- Patient who has had previous mutilating surgery causing sequelae of swallowing and eating
- Uncontrolled infectious pathology
- Patient under 18 years of age
- Patient who is not fluent in French
- Patient with a psychiatric pathology that could disrupt the study or prevent the interpretation of the results.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Caen University Hospital
Caen, France
Actively Recruiting
Research Team
M
Maxime Humbert, MD
CONTACT
E
Emmanuel Babin, PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here